Background: Warfarin dosing after bariatric surgery may be influenced by alterations in gastrointestinal pH, transit time, absorptive surface area, gut microbiota, food intake, and adipose tissue. Objectives: The aim of this study was to describe trends in warfarin dosing after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Setting: Single academic center. Methods: All patients chronically on warfarin anticoagulation before RYGB or SG were retrospectively identified. Indications for anticoagulation, history of bleeding or thrombotic events, perioperative complications, and warfarin dosing were collected. Results: Fifty-three patients (RYGB n = 31, SG n = 22) on chronic warfarin therapy were identified (56.6% female, mean 54.4 ± 11.7 yr of age). Of this cohort, 34.0% had prior venous thromboembolic events, 43.4% had atrial fibrillation, and 5.7% had mechanical cardiac valves. Preoperatively, the average daily dose of warfarin was similar in the RYGB group (8.3 ± 4.1 mg) and SG group (6.9 ± 2.8 mg). One month after surgery, mean daily dose of warfarin was reduced 24.1% in the RYGB group (P
CITATION STYLE
Strong, A. T., Sharma, G., Nor Hanipah, Z., Tu, C., Brethauer, S. A., Schauer, P. R., … Aminian, A. (2018). Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy. Surgery for Obesity and Related Diseases, 14(5), 700–706. https://doi.org/10.1016/j.soard.2017.12.021
Mendeley helps you to discover research relevant for your work.